Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price dropped 23.5% during trading on Saturday . The company traded as low as C$0.09 and last traded at C$0.13. Approximately 119,000 shares were traded during trading, an increase of 588% from the average daily volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Trading Down 23.5%
The company has a market cap of C$19.27 million, a price-to-earnings ratio of -4.64 and a beta of 0.67. The business’s fifty day moving average price is C$0.16 and its 200 day moving average price is C$0.17. The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
See Also
- Five stocks we like better than Devonian Health Group
- What does consumer price index measure?
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- Manufacturing Stocks Investing
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- Investing in the High PE Growth Stocks
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
